"Shortage Reported of Drug for AIDS Patients"

Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

"Shortage Reported of Drug for AIDS Patients"

United Press International (12/17/92)

Abstract: Atlanta--The Centers for Disease Control revealed Thursday that there is a shortage of a drug used to treat toxoplasmosis in AIDS patients. Between Dec. 6 and Dec. 12, the CDC received telephone calls from pharmacies across the nation requesting sulfadiazine-trisulfapyrimidine, or triple sulfa. The drug is commonly used with another drug called pyrimethamine to treat AIDS patients co-infected with toxoplasmosis, which affects the central nervous system. The CDC said the only firm licensed to produce the drug ceased operation in October. Consequently, the Food and Drug Administration is contacting drug companies to try to restore supplies quickly. Physicians should consider using a drug called clindamycin with pyrimethamine to treat acute toxoplasmosis until a commercial source is available, said the CDC. The agency said in the meantime it has acquired a small supply of sulfadiazine--triple sulfa that will be provided to people with acute disease who cannot tolerate clindamycin.

921217
AD922452

Copyright © 1992 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.

Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.